CN101555274B - 一种多肽固相合成比法卢定粗品的制备方法 - Google Patents
一种多肽固相合成比法卢定粗品的制备方法 Download PDFInfo
- Publication number
- CN101555274B CN101555274B CN200910051311XA CN200910051311A CN101555274B CN 101555274 B CN101555274 B CN 101555274B CN 200910051311X A CN200910051311X A CN 200910051311XA CN 200910051311 A CN200910051311 A CN 200910051311A CN 101555274 B CN101555274 B CN 101555274B
- Authority
- CN
- China
- Prior art keywords
- resin
- polypeptide
- fmoc
- gly
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 67
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 56
- 108010055460 bivalirudin Proteins 0.000 title claims abstract description 42
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 title claims abstract description 37
- 229960001500 bivalirudin Drugs 0.000 title claims abstract description 37
- 238000010532 solid phase synthesis reaction Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000012043 crude product Substances 0.000 title abstract description 5
- 239000011347 resin Substances 0.000 claims abstract description 95
- 229920005989 resin Polymers 0.000 claims abstract description 95
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- -1 bicyclic amidine Chemical class 0.000 claims abstract description 31
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 238000009833 condensation Methods 0.000 claims abstract description 23
- 230000005494 condensation Effects 0.000 claims abstract description 23
- 238000005520 cutting process Methods 0.000 claims abstract description 20
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 17
- 125000006239 protecting group Chemical group 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 44
- 230000001681 protective effect Effects 0.000 claims description 31
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 150000003053 piperidines Chemical class 0.000 claims description 20
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 claims description 14
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 claims description 11
- 239000012317 TBTU Substances 0.000 claims description 11
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 11
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 claims description 11
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 claims description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 10
- 239000007821 HATU Substances 0.000 claims description 8
- 230000001186 cumulative effect Effects 0.000 claims description 8
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 claims description 8
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000012535 impurity Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000003875 Wang resin Substances 0.000 description 6
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 3
- UIDUKLCLJMXFEO-UHFFFAOYSA-N propylsilane Chemical class CCC[SiH3] UIDUKLCLJMXFEO-UHFFFAOYSA-N 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- JBLIDPPHFGWTKU-UHFFFAOYSA-N 2,6-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=CC=C1Cl JBLIDPPHFGWTKU-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000237677 Hirudinaria Species 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu | 式I |
Boc-D-Phe1-Pro2-Arg(Pbf)3-Pro4-Gly5-Gly6-Gly7-Gly8-Asn(Trt)9-Gly10-Asp(OtBu)11-Phe12-Glu(OtBu)13-Glu(OtBu)14-Ile15-Pro16-Glu(OtBu)17-Glu(OtBu)18-Tyr(tBu)19-Leu20-树脂 | 式II |
D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu | 式I |
Boc-D-Phe1-Pro2-Arg(Pbf)3-Pro4-Gly5-Gly6-Gly7-Gly8-Asn(Trt)9-Gly10-Asp(OtBu)11-Phe12-Glu(OtBu)13-Glu(OtBu)14-Ile15-Pro16-Glu(OtBu)17-Glu(OtBu)18-Tyr(tBu)19-Leu20-树脂 | 式II |
Fmoc | 9芴甲氧羰基 |
Boc | 叔丁氧羰基 |
DMF | N,N-二甲基甲酰胺 |
KSCN | 硫氰化钾 |
DBU | 二环脒(双脒类化合物) |
HOBt | 1-羟基苯并三唑 |
DIC | N,N′-二异丙基碳二亚胺 |
TBTU | 苯并三唑四甲基脲四氟硼酸 |
NMM | N-甲基吗啉 |
Pbf | 2,2,4,6,7-五甲基苯并呋喃-5-磺酰基 |
Opfp | 五氟苯酯 |
TFA | 三氟乙酸 |
TIS | 三乙丙基硅烷 |
MTBE | 甲基叔丁基醚 |
HOOBT | 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 |
HATU | O-(7-氮杂苯并三唑-1-基)-N,N,N′,N′-四甲基脲六氟磷酸 |
TBTU | O-(苯并三唑-1-基)-N,N,N,N-四甲基脲四氟硼酸 |
PyBOP | (苯并三唑-1-基-氧)三吡咯烷鏻六氟磷酸 |
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910051311XA CN101555274B (zh) | 2009-05-15 | 2009-05-15 | 一种多肽固相合成比法卢定粗品的制备方法 |
US12/781,037 US20100292436A1 (en) | 2009-05-15 | 2010-05-17 | Method for producing bivalirudin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910051311XA CN101555274B (zh) | 2009-05-15 | 2009-05-15 | 一种多肽固相合成比法卢定粗品的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101555274A CN101555274A (zh) | 2009-10-14 |
CN101555274B true CN101555274B (zh) | 2013-08-21 |
Family
ID=41173572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910051311XA Active CN101555274B (zh) | 2009-05-15 | 2009-05-15 | 一种多肽固相合成比法卢定粗品的制备方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20100292436A1 (zh) |
CN (1) | CN101555274B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101094867B (zh) | 2004-10-19 | 2011-08-24 | 隆萨股份公司 | 用于固相肽合成的方法 |
CN101906150B (zh) * | 2010-06-28 | 2013-01-09 | 上海昂博生物技术有限公司 | 一种比法卢定的制备方法 |
CN102286076B (zh) * | 2011-06-23 | 2014-03-12 | 成都圣诺科技发展有限公司 | 比伐卢定的制备方法 |
WO2013042129A1 (en) | 2011-09-23 | 2013-03-28 | Natco Pharma Limited | Improved process for preparation of bivalirudin |
CN103122026A (zh) * | 2012-06-15 | 2013-05-29 | 上海昂博生物技术有限公司 | 一种艾塞那肽粗品的固相制备方法 |
US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
DK2976325T3 (en) | 2013-03-21 | 2017-06-06 | Sanofi Aventis Deutschland | SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID |
CN104558161B (zh) * | 2013-10-23 | 2017-10-17 | 上海第一生化药业有限公司 | 比伐芦定中间体的固相合成方法 |
CN104558159B (zh) * | 2013-10-23 | 2018-03-13 | 上海上药第一生化药业有限公司 | 比伐芦定中间体的固相合成方法 |
CN104558162B (zh) * | 2013-10-23 | 2018-11-02 | 上海上药第一生化药业有限公司 | 比伐芦定中间体的固相合成方法 |
CN104558160B (zh) * | 2013-10-23 | 2018-01-16 | 上海第一生化药业有限公司 | 比伐芦定中间体的固相合成方法 |
CN108383905A (zh) * | 2016-12-30 | 2018-08-10 | 江苏金斯瑞生物科技有限公司 | 一种比伐卢定的制备方法 |
CN112424216A (zh) * | 2018-06-19 | 2021-02-26 | 上海胜泽泰医药科技有限公司 | 比伐卢定的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101033249A (zh) * | 2006-03-10 | 2007-09-12 | 周逸明 | 固相多肽合成比筏芦定的制备方法 |
CN101094867A (zh) * | 2004-10-19 | 2007-12-26 | 隆萨股份公司 | 用于固相肽合成的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US5242810A (en) * | 1990-12-07 | 1993-09-07 | Biogen, Inc. | Bifunctional inhibitors of thrombin and platelet activation |
AT404538B (de) * | 1995-07-12 | 1998-12-28 | Wewalka Gmbh | Vorrichtung zur herstellung von wickeln aus teigblättern und trennblättern |
US5691314A (en) * | 1996-03-18 | 1997-11-25 | The Medical College Of Hampton Roads | Adjunctive therapy |
CN101906150B (zh) * | 2010-06-28 | 2013-01-09 | 上海昂博生物技术有限公司 | 一种比法卢定的制备方法 |
-
2009
- 2009-05-15 CN CN200910051311XA patent/CN101555274B/zh active Active
-
2010
- 2010-05-17 US US12/781,037 patent/US20100292436A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101094867A (zh) * | 2004-10-19 | 2007-12-26 | 隆萨股份公司 | 用于固相肽合成的方法 |
CN101033249A (zh) * | 2006-03-10 | 2007-09-12 | 周逸明 | 固相多肽合成比筏芦定的制备方法 |
Non-Patent Citations (1)
Title |
---|
LJ Cruz et al.Total Solid-Phase Synthesis of Marine Cyclodepsipeptide IB-01212.《J.Org.Chem.》.2005,第71卷(第9期),第3340页右栏第2段. * |
Also Published As
Publication number | Publication date |
---|---|
CN101555274A (zh) | 2009-10-14 |
US20100292436A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101555274B (zh) | 一种多肽固相合成比法卢定粗品的制备方法 | |
CN101906150B (zh) | 一种比法卢定的制备方法 | |
CN101033249B (zh) | 固相多肽合成比筏芦定的制备方法 | |
CN103242431B (zh) | 一种比伐卢定的制备方法 | |
White et al. | Expediting the Fmoc solid phase synthesis of long peptides through the application of dimethyloxazolidine dipeptides | |
US20110160431A1 (en) | Production of peptides containing poly-gly sequences using fmoc chemistry | |
CN102199205A (zh) | 一种多肽胸腺法新的合成方法 | |
WO2012174816A1 (zh) | 比伐卢定的制备方法 | |
CN103374054A (zh) | 一步法固相合成多肽的方法 | |
CN101747426B (zh) | 一种合成普兰林肽的方法 | |
US20170029467A1 (en) | Method of producing bivalirudin | |
MXPA06011904A (es) | Procesos para preparar eptifibatido. | |
CN101475631A (zh) | 比伐卢定的液相合成方法 | |
CN102164608A (zh) | 制备普兰林肽的方法 | |
CN108047329A (zh) | 一种阿巴帕肽的制备方法 | |
CN103333239A (zh) | 固相合成胰高血糖素 | |
CN103333237A (zh) | 一种固相片段法合成艾塞那肽 | |
CN104072585A (zh) | 一种合成艾替班特的方法 | |
AU2008271608A1 (en) | Process for the production of pramlintide | |
CN102174082A (zh) | 一种艾塞那肽的制备方法 | |
CN104004064A (zh) | 一种布舍瑞林的制备方法 | |
CN102229649B (zh) | 一种机体保护多肽(bpc 157肽)的制备方法 | |
CN103951744A (zh) | 一种固相树脂及其制备方法和用途 | |
CN110054662A (zh) | 一种固相合成Etelcalcetide的方法 | |
CN105273062A (zh) | 片段缩合制备比伐卢定的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SHANGHAI AMBIOPHARM, INC. Effective date: 20110422 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201417 NO. 388, CHUGONG ROAD, FENGXIAN BRANCH AREA, CHEMICAL INDUSTRIAL ZONE, SHANGHAI TO: 570125 ROOM 1901, SOUTH OCEAN BUILDING, NO. 81, BINHAI AVENUE, HAIKOU CITY, HAINAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110422 Address after: 1901 room 570125, Nanyang building, 81 Binhai Avenue, Hainan, Haikou Applicant after: Hainan Shuangcheng Pharmaceuticals Co., Ltd. Address before: 201417 No. 388, Chu Road, Fengxian District, Shanghai chemical industry zone Applicant before: Shanghai Angbo Biological Technology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |